{"entity":{"id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","aka":[],"tldr":"A phase 1/2 trial of CTD402 CAR T Cell Injection in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Imviva Bio, now recruiting.","summary":"A Study of CTD402 in T-ALL/LBL Patients is a phase 1/2 interventional study registered as NCT07070219 by Imviva Bio, with 118 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-09-30. Interventions recorded: CTD402 CAR T Cell Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07070219","url":"https://clinicaltrials.gov/study/NCT07070219"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07070219","phase":"1/2","setting":"A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)","sponsor":"Imviva Bio","enrolled":118,"outcomes":[]},"route":"/trials/nct07070219/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}